Dr. William Cho

Department of Clinical Oncology

Queen Elizabeth Hospital, China

Scientific Officer

Email: [email protected]

Qualifications

2006 Ph.D., the Baptist University of Hong Kong, Biochemistry

1991 M.S., the Chinese University of Hong Kong, Biochemistry

1987 B.S., the Chinese University of Hong Kong, Biochemistry

Publications (selected)

1. Noroozi-Karimabad, M., Alimohammadi, M., Mafi, A., et al. (2026). Targeting mitochondrial metabolism in renal cell carcinoma with melatonin: Preclinical evidence and clinical perspectives. Tissue & Cell, 103, Article 103617.
2. Wang, H. C., Cong, B. S., Cho, W. C., et al. (2026). Hypergraph-graph collaborative modeling for the prediction of benefit from immunotherapy in non-small cell lung cancer. Engineering Applications of Artificial Intelligence, 181, Article 115313.
3. Jiang, Y. F., Teng, X. Z., Cho, W. C., et al. (2026). Bridging multi-omics to routine precision oncology: Biologically informed knowledge transfer for precision pCR prediction in neoadjuvant immunotherapy. Journal of Clinical Oncology, 44(16_suppl), e12569.
4. Cho, W. C., Yu, A. C. S., Cheuk, W., et al. (2026). The molecular landscape of CASTLE: A rare thymus-like head and neck cancer. International Journal of Molecular Sciences, 27(8), Article 3501.
5. Cho, W. C., Yao, Q. Q., Wang, Y. Y., et al. (2026). Monitoring molecular residual disease in colorectal cancer using tumor-informed ctDNA analysis. Cancer Research, 86(7_Supplement), Abstract 7826.
6. To, K. K. W., Wang, L. L., Zuo, Z., et al. (2026). Multi-omics identifies EMT and PI3K/AKT pathways as mechanisms for Astragalus membranaceus polysaccharide-mediated reversal of osimertinib resistance. Cancer Research, 86(7_Supplement), Abstract 7045.
7. Zhang, L. C., Cho, W. C. S., Joshua, L., et al. (2026). Quantitative 3D histology: Million-cell-scale spatial multi-omics in intact FFPE specimens. Cancer Research, 86(7_Supplement), Abstract 713.
8. Bhangdia, K., May, M. L., Kocarnik, J. M., et al. (2026). Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: A systematic analysis for the Global Burden of Disease Study 2023. Lancet Oncology, 27(3), 302-326.
9. Ye, J. J., Xie, Y. D., Wang, J., et al. (2026). Intratumoral androgens and genetic variants driving therapy resistance in prostate cancer. Research, 2026, Article 1128.
10. Hashemi, M., Heshmatzad, K., Shahsavan, G., et al. (2026). Natural bioactive molecules and chemotherapeutics synergism for enhanced cancer therapy. Nutrition & Metabolism, 23(1), Article 38.
11. Wang, Z. M., Liu, H., Liang, J. W., et al. (2026). Ferroptosis induction enhances anti-PD-1 efficacy in NSCLC via HIF-1alpha/PD-L1 modulation. Translational Oncology, 65, Article 102685.
12. Li, D. N., Liu, X. N., Lu, J., et al. (2026). AQP7 suppresses cell stemness and metastasis by targeting Wnt signaling in basal-like breast cancer. Expert Opinion on Therapeutic Targets, 30(1), 75-86.
13. Shang, H. C., Cho, W., Xing, Y. W. (2026). Cancer therapy-related cardiovascular toxicity: Current progress and future perspectives. Seminars in Cancer Biology, 120, 1-3.
14. Safari, M. H., Farahani, N., Ojaroodi, A. F., et al. (2026). Long non-coding RNAs and therapeutic resistance in multiple myeloma: From molecular insights to clinical applications. Clinical and Experimental Medicine, 26(1), Article 114.
15. Jiang, C., Tuo, Z. T., Wusiman, D., et al. (2026). The implications of radiotherapy-induced cellular senescence for cancer treatment and tumor microenvironment modulation. International Journal of Biological Sciences, 22(7), 3488-3508.
16. Mundekkad, D., Cho, W. C. S. (2026). Biomimetic FeO nanozymes promote apoptosis in breast cancer cell lines via free radical scavenging and inhibition of RelA/p65. Current Pharmaceutical Biotechnology, 27(5), 593-605.
17. Yeung, S. F., Chen, J. X., Yuen, M. M. H., et al. (2026). Pan-RAS inhibitors show preclinical efficacy against oncogenic NRAS variants in melanoma. Cancer Science, 117(Suppl. 1), 116.